PL365134A1 - Pochodne imidazolu - Google Patents

Pochodne imidazolu

Info

Publication number: PL365134A1
Authority: PL; Poland
Prior art keywords: imidazole derivatives; imidazole; derivatives
Prior art date: 2000-07-31

Application number

PL01365134A

Other languages

English (en)

Inventor

Michael Kirk Ahlijanian

Christopher Blair Cooper

Christopher John Helal

Lit-Fui Lau

Frank Samuel Menniti

Mark Allen Sanner

Patricia Ann Seymour

Anabella Villalobos

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-31

Filing date

2001-07-25

Publication date

2004-12-27

2001-07-25 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-12-27 Publication of PL365134A1 publication Critical patent/PL365134A1/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Communicable Diseases (AREA)

PL01365134A 2000-07-31 2001-07-25 Pochodne imidazolu PL365134A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22172400P	2000-07-31	2000-07-31
PCT/IB2001/001335 WO2002010141A1 (en)	2000-07-31	2001-07-25	Imidazole derivatives

Publications (1)

Publication Number	Publication Date
PL365134A1 true PL365134A1 (pl)	2004-12-27

Family

ID=22829075

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL01365134A PL365134A1 (pl)	2000-07-31	2001-07-25	Pochodne imidazolu

Country Status (36)

Country	Link
EP (1)	EP1305295A1 (pl)
JP (2)	JP4166084B2 (pl)
KR (1)	KR20030019644A (pl)
CN (1)	CN1444567A (pl)
AP (1)	AP2001002232A0 (pl)
AR (1)	AR032629A1 (pl)
AU (1)	AU2001270944A1 (pl)
BG (1)	BG107469A (pl)
BR (1)	BR0112862A (pl)
CA (1)	CA2418115A1 (pl)
CR (1)	CR6861A (pl)
CZ (1)	CZ2003225A3 (pl)
DO (1)	DOP2001000220A (pl)
EA (1)	EA200300097A1 (pl)
EC (1)	ECSP034445A (pl)
EE (1)	EE200300049A (pl)
GT (1)	GT200100147A (pl)
HR (1)	HRP20030048A2 (pl)
HU (1)	HUP0303069A3 (pl)
IL (1)	IL153787A0 (pl)
IS (1)	IS6662A (pl)
MA (1)	MA26932A1 (pl)
MX (1)	MXPA03000939A (pl)
NO (1)	NO20030472L (pl)
NZ (1)	NZ523272A (pl)
OA (1)	OA12345A (pl)
PA (1)	PA8523701A1 (pl)
PE (1)	PE20020337A1 (pl)
PL (1)	PL365134A1 (pl)
PY (1)	PY0117895A (pl)
SK (1)	SK1042003A3 (pl)
SV (1)	SV2002000571A (pl)
TN (1)	TNSN01114A1 (pl)
UY (1)	UY26862A1 (pl)
WO (1)	WO2002010141A1 (pl)
ZA (1)	ZA200300819B (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE538794T1 (de)	1999-01-13	2012-01-15	Bayer Healthcare Llc	Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en)	1999-01-13	2008-04-01	Bayer Pharmaceuticals Corporation	ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003068229A1 (en)	2002-02-11	2003-08-21	Bayer Pharmaceuticals Corporation	Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
MXPA04007832A (es)	2002-02-11	2005-09-08	Bayer Pharmaceuticals Corp	Aril-ureas con actividad inhibitoria de angiogenesis.
EP1527070B1 (en)	2002-06-14	2013-01-09	Merck Serono SA	Azole methylidene cyanide derivatives and their use as protein kinase modulators
US7141561B2 (en)	2002-07-25	2006-11-28	Sanofi-Aventis Deutschland Gmbh	Substituted diaryl heterocycles, process for their preparation and their use as medicaments
DE10233817A1 (de) *	2002-07-25	2004-02-12	Aventis Pharma Deutschland Gmbh	Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0308968D0 (en) *	2003-04-17	2003-05-28	Glaxo Group Ltd	Medicaments
WO2004113274A2 (en)	2003-05-20	2004-12-29	Bayer Pharmaceuticals Corporation	Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru)	2003-07-23	2008-10-30	Байер Фамэсьютиклс Копэрейшн	Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
CN1934091B (zh) *	2004-03-23	2012-02-08	辉瑞产品公司	治疗神经变性障碍的咪唑化合物
CN101010315A (zh)	2004-04-30	2007-08-01	拜耳制药公司	用于治疗癌症的取代的吡唑基脲衍生物
US7928264B2 (en)	2004-09-21	2011-04-19	Astellas Pharma Inc.	Aminoalcohol derivatives
US20080207594A1 (en)	2005-05-04	2008-08-28	Davelogen Aktiengesellschaft	Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
EP1928437A2 (en)	2005-08-26	2008-06-11	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
WO2007034326A2 (en)	2005-09-22	2007-03-29	Pfizer Products Inc.	Imidazole compounds for the treatment of neurological disorders
EP1940389A2 (en)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
US20070112017A1 (en)	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
MY149143A (en)	2006-01-18	2013-07-15	Amgen Inc	Thiazole compounds as protien kinase b (pkb) inhibitors
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
AU2007312165A1 (en)	2006-10-21	2008-04-24	Abbott Gmbh & Co. Kg	Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2009017453A1 (en) *	2007-07-30	2009-02-05	Astrazeneca Ab	New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
JP5756011B2 (ja) *	2008-04-24	2015-07-29	アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー	グリコーゲン合成酵素キナーゼ３（ｇｓｋ−３）としての１−（７−（ヘキサヒドロピロロ［３，４−ｃ］ピロール−２（１ｈ）−イル）キノリン−４−イル）−３−（ピラジン−２−イル）尿素誘導体とその関連化合物
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CA2810954A1 (en)	2010-09-27	2012-04-05	Abbott Gmbh & Co. Kg	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en)	2010-12-30	2015-07-28	AbbVie Deutschland GmbH & Co. KG	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
AU2013355054B2 (en)	2012-12-07	2017-08-24	Chemocentryx, Inc.	Diazole lactams
US9169248B2 (en) *	2012-12-21	2015-10-27	Chemocentryx, Inc.	Diazole amides
JP6616190B2 (ja) *	2014-02-07	2019-12-04	国立大学法人東京医科歯科大学	筋形成促進剤、筋萎縮抑制剤、医薬組成物及びｔａｚ活性化剤
CA3208241A1 (en) *	2015-08-31	2017-03-09	Nutramax Laboratories, Inc.	Compositions comprising magnolia, phellodendron, theanine and/or whey protein
GB201605126D0 (en) *	2016-03-24	2016-05-11	Univ Nottingham	Inhibitors and their uses
CN109310677A (zh)	2016-04-07	2019-02-05	凯莫森特里克斯股份有限公司	通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷
CN111018840B (zh) *	2017-10-25	2022-09-09	西南大学	3-咪唑取代的靛红唑醇类化合物及其制备方法和医药应用
US20210236466A1 (en) *	2018-07-03	2021-08-05	Ifm Due, Inc.	Compounds and compositions for treating conditions associated with sting activity
EP3920885A1 (en)	2019-02-08	2021-12-15	Frequency Therapeutics, Inc.	Valproic acid compounds and wnt agonists for treating ear disorders
GB201908424D0 (en) *	2019-06-12	2019-07-24	Imp College Innovations Ltd	Novel compounds
KR20250030524A (ko)	2019-08-09	2025-03-05	화이자 인코포레이티드	(s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의고체 상태 형태 및 이의 용도
US11884634B2 (en)	2019-08-09	2024-01-30	Pfizer Inc.	Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
WO2022079290A2 (en) *	2020-10-16	2022-04-21	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Cullin ring ubiquitin ligase compounds and uses thereof
CN112250636A (zh) *	2020-11-09	2021-01-22	广西科技大学	5-氨基咪唑类化合物及其合成方法
AU2022271290A1 (en)	2021-05-07	2023-11-23	Kymera Therapeutics, Inc.	Cdk2 degraders and uses thereof
CA3230245A1 (en)	2021-09-01	2023-03-09	Springworks Therapeutics, Inc.	Synthesis of nirogacestat
US11504354B1 (en)	2021-09-08	2022-11-22	SpringWorks Therapeutics Inc..	Chlorinated tetralin compounds and pharmaceutical compositions
CN116983313B (zh) *	2023-07-13	2026-01-27	四川大学	Nu6300的新用途
WO2026024674A1 (en)	2024-07-22	2026-01-29	Genesis Therapeutics, Inc.	Methods of treating skp2-associated cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5401851A (en) *	1992-06-03	1995-03-28	Eli Lilly And Company	Angiotensin II antagonists
US5760246A (en) *	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987385B (en) *	1997-08-19	2000-04-18	Lilly Co Eli	Growth hormone secretagogues.
ZA987383B (en) *	1997-08-19	2000-02-17	Lilly Co Eli	Treatment of congestive heart failure with growth hormone secretagogues.
KR100581199B1 (ko) *	1998-06-19	2006-05-17	카이론 코포레이션	글리코겐 신타제 키나제 3의 억제제
WO2000021550A2 (en) *	1998-10-13	2000-04-20	President And Fellows Of Harvard College	Methods and compositions for treating neurodegenerative diseases
CO5160260A1 (es) *	1999-02-19	2002-05-30	Lilly Co Eli	Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
EP1106180B1 (en) *	1999-12-08	2003-11-12	Centre National de la Recherche Scientifique (CNRS)	Use of hymenialdisine or derivatives thereof in the manufacture of medicaments

2001
- 2001-07-23 PY PY200100117895A patent/PY0117895A/es unknown
- 2001-07-23 GT GT200100147A patent/GT200100147A/es unknown
- 2001-07-25 EP EP01949833A patent/EP1305295A1/en not_active Withdrawn
- 2001-07-25 HU HU0303069A patent/HUP0303069A3/hu unknown
- 2001-07-25 CA CA002418115A patent/CA2418115A1/en not_active Abandoned
- 2001-07-25 PE PE2001000752A patent/PE20020337A1/es not_active Application Discontinuation
- 2001-07-25 OA OA1200300017A patent/OA12345A/en unknown
- 2001-07-25 EA EA200300097A patent/EA200300097A1/ru unknown
- 2001-07-25 PL PL01365134A patent/PL365134A1/pl not_active Application Discontinuation
- 2001-07-25 AU AU2001270944A patent/AU2001270944A1/en not_active Abandoned
- 2001-07-25 HR HR20030048A patent/HRP20030048A2/hr not_active Application Discontinuation
- 2001-07-25 NZ NZ523272A patent/NZ523272A/en unknown
- 2001-07-25 SK SK104-2003A patent/SK1042003A3/sk not_active Application Discontinuation
- 2001-07-25 EE EEP200300049A patent/EE200300049A/xx unknown
- 2001-07-25 MX MXPA03000939A patent/MXPA03000939A/es active IP Right Grant
- 2001-07-25 CZ CZ2003225A patent/CZ2003225A3/cs unknown
- 2001-07-25 KR KR10-2003-7001455A patent/KR20030019644A/ko not_active Ceased
- 2001-07-25 JP JP2002516273A patent/JP4166084B2/ja not_active Expired - Fee Related
- 2001-07-25 IL IL15378701A patent/IL153787A0/xx unknown
- 2001-07-25 WO PCT/IB2001/001335 patent/WO2002010141A1/en not_active Ceased
- 2001-07-25 CN CN01813397A patent/CN1444567A/zh active Pending
- 2001-07-25 BR BR0112862-0A patent/BR0112862A/pt not_active IP Right Cessation
- 2001-07-26 AP APAP/P/2001/002232A patent/AP2001002232A0/en unknown
- 2001-07-27 SV SV2001000571A patent/SV2002000571A/es not_active Application Discontinuation
- 2001-07-27 DO DO2001000220A patent/DOP2001000220A/es unknown
- 2001-07-30 UY UY26862A patent/UY26862A1/es not_active Application Discontinuation
- 2001-07-30 TN TNTNSN01114A patent/TNSN01114A1/fr unknown
- 2001-07-30 AR ARP010103637A patent/AR032629A1/es unknown
- 2001-07-31 PA PA20018523701A patent/PA8523701A1/es unknown
2002
- 2002-12-18 CR CR6861A patent/CR6861A/es not_active Application Discontinuation
- 2002-12-19 IS IS6662A patent/IS6662A/is unknown
2003
- 2003-01-16 BG BG107469A patent/BG107469A/bg unknown
- 2003-01-20 MA MA27004A patent/MA26932A1/fr unknown
- 2003-01-22 EC EC2003004445A patent/ECSP034445A/es unknown
- 2003-01-29 ZA ZA200300819A patent/ZA200300819B/en unknown
- 2003-01-30 NO NO20030472A patent/NO20030472L/no not_active Application Discontinuation
2008
- 2008-05-19 JP JP2008131176A patent/JP2008255123A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
ECSP034445A (es)	2003-03-10
TNSN01114A1 (fr)	2005-11-10
NO20030472D0 (no)	2003-01-30
EA200300097A1 (ru)	2003-06-26
SV2002000571A (es)	2002-10-24
MA26932A1 (fr)	2004-12-20
GT200100147A (es)	2002-06-25
DOP2001000220A (es)	2002-05-15
OA12345A (en)	2004-04-13
CN1444567A (zh)	2003-09-24
PY0117895A (es)	2003-11-03
SK1042003A3 (en)	2004-05-04
AP2001002232A0 (en)	2001-09-30
HUP0303069A2 (hu)	2004-03-01
JP2004505111A (ja)	2004-02-19
JP4166084B2 (ja)	2008-10-15
AU2001270944A1 (en)	2002-02-13
CA2418115A1 (en)	2002-02-07
NO20030472L (no)	2003-03-27
PE20020337A1 (es)	2002-05-08
BG107469A (bg)	2003-09-30
PA8523701A1 (es)	2002-04-25
HUP0303069A3 (en)	2004-04-28
ZA200300819B (en)	2004-04-20
AR032629A1 (es)	2003-11-19
HRP20030048A2 (en)	2003-04-30
IS6662A (is)	2002-12-19
JP2008255123A (ja)	2008-10-23
IL153787A0 (en)	2003-07-31
BR0112862A (pt)	2003-07-01
CR6861A (es)	2004-03-11
EP1305295A1 (en)	2003-05-02
CZ2003225A3 (cs)	2004-02-18
MXPA03000939A (es)	2003-06-24
WO2002010141A1 (en)	2002-02-07
EE200300049A (et)	2004-10-15
NZ523272A (en)	2004-08-27
UY26862A1 (es)	2002-02-28
KR20030019644A (ko)	2003-03-06

Legal Events

Date	Code	Title	Description
2010-03-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
EE200300049A (et)	2004-10-15	Imidasooli derivaadid
ATE360620T1 (de)	2007-05-15	Imidazolderivate
NO20025517L (no)	2002-11-18	Triazolderivater
ATE425147T1 (de)	2009-03-15	Imidazolderivate
ATE333445T1 (de)	2006-08-15	Pyrazolderivate
DK1292604T3 (da)	2009-06-15	2-Aminocarbonyl-9H-purinderivater
DK1224180T3 (da)	2003-10-20	Substituerede azoler
ATE288437T1 (de)	2005-02-15	Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e
DK1280809T3 (da)	2005-11-07	Antitumorecteinascidinderivater
ATE298332T1 (de)	2005-07-15	Decahydro-isochinolinderivate
DK1571140T3 (da)	2009-03-09	Substituerede C-cyjklohexylmethylamin-derivater
AR028602A1 (es)	2003-05-14	Derivados de pirrol
ATE282021T1 (de)	2004-11-15	Substituierte aminomethyl-phenyl- cyclohexanderivate
DK1322593T3 (da)	2004-10-11	O-substituerede-6-methyl-tramadol-derivater
DK1246791T3 (da)	2005-02-14	Aminomethyl-phenyl-cyklohexanonderivater
DK1322590T3 (da)	2007-09-03	Substituerede 5-amino-1-penten-3-ol-derivater
ATE374776T1 (de)	2007-10-15	Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no)	2002-09-13	2-fenylpyran-4-on-derivater
DK1246793T3 (da)	2005-02-21	Substituerede aminomethyl-phenyl-cyclohexanderivater